



**Westchester Regional Emergency Medical Advisory Committee
EPINEPHRINE AUTO-INJECTOR COLLABORATIVE AGREEMENT
(EMS)**

**Between an EMS Agency Epinephrine Auto-Injector Provider and Emergency Health Care Provider for the
Provision of Epinephrine Auto-Injector Administration in New York State**

The following agreement stands between the _____
(Participating EMS Agency) and _____, (Physician / Hospital)
Emergency Health Care Provider (EHCP), authorizing the use of Epinephrine Auto-Injectors Devices for the
treatment of anaphylaxis, by Certified First Responder (CFR) and Emergency Medical Technician-Basic (EMT-
B) providers of said agency who have received training required by the Commissioner of the New York State
Department of Health and supervised by said EHCP. The following conditions must be observed by all
participating members of the agency:

1. The agency and its trained providers shall possess and administer Epinephrine auto-injectors according to the current NYS BLS and Westchester REMAC Protocols for treatment of anaphylaxis, and NYS DOH Bureau of EMS policies related to the administration of Epinephrine auto-injectors by BLS personnel.
2. The agency shall acquire, store, account, and dispose of used auto-injectors according to the written polices developed in conjunction with the EHCP. **(SEE ATTACHED.)**
3. The agency is responsible for the purchase of Epinephrine auto-injector devices, and the maintenance of an adequate stock so that Epinephrine auto-injectors are available at all times.
4. Providers of the agency are responsible to store Epinephrine auto-injector devices in accordance with NYS DOH BEMS polices regarding the storage and safe guarding of medications administered by EMT-B's.
5. Providers are responsible to inspect the Epinephrine auto-injector devices for expiration date and replace the units as necessary.
6. Use of an Epinephrine auto-injector is limited to providers who have attended a course of instruction based upon the curriculum outlined by the NYS DOH on the diagnosis of anaphylaxis and the proper use of an Epinephrine auto-injector device by the EHCP or approved designee. **(SEE ATTACHED.)**
7. Use of an Epinephrine auto-injector device is limited to the treatment of anaphylaxis where patients exhibit respiratory distress and/or cardiovascular compromise. Patients receiving Epinephrine must be closely monitored and transported to the nearest hospital.
8. Use of an Epinephrine auto-injector shall be properly documented on a NYSDOH Patient Care Report (PCR), or other NYSDOH approved form. A copy of the PCR must be forwarded to the EHCP as soon as possible.
9. A Westchester Regional incident report shall be completed for all patients receiving an Epinephrine auto-injector device and must be forwarded to the Westchester REMAC **within 48 hours with copies of the PCR.**
10. The agency shall participate in any Quality Improvement (QI) projects requested by the NYSDOH BEMS, the State Emergency Medical Advisory Committee (SEMAC) and the Westchester REMAC.
11. Prior to the implementation of an Epinephrine Auto-injector program, the agency shall first file with a Notice of Intent to Possess and Use Epinephrine Auto Injectors (DOH-4188), this collaborative agreement, and any aforementioned attachments.

The responsibilities of the EHCP shall include, but not be limited to the following:

1. Provide the agency with the appropriate initial instruction and continuing education in the assessment of anaphylaxis and the proper use of an Epinephrine auto-injector device.
2. Provide the agency with the authorization to purchase Epinephrine auto-injector devices.
3. Review all uses of Epinephrine auto-injector devices and provide appropriate QI feedback.

Signature of EMS Agency Executive Officer

Date

Signature of EHCP (MD or Hospital Designee)

Date

WREMAC/EPI/EMS/2012/ Local Reproduction Authorized / Replaces all previous versions